Tumor Heterogeneity and Tumor Immunity: A Chicken-and-Egg Problem

Publication date: Available online 8 May 2016
Source:Trends in Immunology
Author(s): Stefani Spranger
The overall mutational burden of a tumor is considered to be a predictive marker for the success of checkpoint blockade therapy. A recent study by McGranahan et al. reframes this notion by showing that clonal expression of neoantigens by tumor cells, rather than overall mutational burden, determines the response to checkpoint blockade therapy.



from #ENT via xlomafota13 on Inoreader http://ift.tt/24EdkOs
via IFTTT